Novartis AG PE Ratio 2006-2018 | NVS

Current and historical p/e ratio for Novartis AG (NVS) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Novartis AG PE ratio as of November 21, 2018 is 17.22.
Novartis AG PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2018-11-21 89.03 15.62
2018-09-30 86.16 $5.70 15.12
2018-06-30 75.54 $5.89 12.83
2018-03-31 80.85 $3.41 23.71
2017-12-31 81.04 $3.25 24.94
2017-09-30 82.87 $2.81 29.49
2017-06-30 80.57 $2.74 29.40
2017-03-31 71.69 $2.66 26.95
2016-12-31 67.87 $2.80 24.24
2016-09-30 73.57 $2.84 25.91
2016-06-30 76.88 $2.80 27.46
2016-03-31 67.50 $2.80 24.11
2015-12-31 77.20 $7.28 10.60
2015-09-30 82.47 $7.45 11.07
2015-06-30 88.23 $7.99 11.04
2015-03-31 88.48 $8.27 10.70
2014-12-31 80.86 $4.14 19.53
2014-09-30 82.14 $4.35 18.88
2014-06-30 79.00 $3.94 20.05
2014-03-31 74.19 $3.94 18.83
2013-12-31 67.88 $3.72 18.25
2013-09-30 64.78 $3.73 17.37
2013-06-30 59.71 $3.84 15.55
2013-03-31 60.16 $3.92 15.35
2012-12-31 51.50 $3.90 13.21
2012-09-30 49.84 $3.55 14.04
2012-06-30 45.48 $3.55 12.81
2012-03-31 45.08 $3.55 12.70
2011-12-31 44.52 $3.80 11.72
2011-09-30 43.43 $4.26 10.20
2011-06-30 47.59 $4.24 11.22
2011-03-31 42.33 $4.19 10.10
2010-12-31 44.02 $4.28 10.29
2010-09-30 43.07 $4.35 9.90
2010-06-30 36.08 $4.28 8.43
2010-03-31 40.40 $4.11 9.83
2009-12-31 39.21 $3.69 10.63
2009-09-30 36.29 $3.34 10.87
2009-06-30 29.38 $3.34 8.80
2009-03-31 27.25 $3.44 7.92
2008-12-31 34.33 $3.59 9.56
2008-09-30 36.45 $3.34 10.91
2008-06-30 37.97 $5.39 7.04
2008-03-31 35.34 $5.26 6.72
2007-12-31 36.40 $5.16 7.05
2007-09-30 36.83 $5.45 6.76
2007-06-30 37.58 $3.28 11.46
2007-03-31 36.61 $3.15 11.62
2006-12-31 37.78 $3.06 12.35
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $201.503B $49.109B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $392.911B 18.42
Pfizer (PFE) United States $259.128B 14.61
Merck (MRK) United States $201.621B 17.47
AbbVie (ABBV) United States $132.506B 11.76
Eli Lilly (LLY) United States $121.525B 21.36
Sanofi (SNY) France $112.036B 13.87
Novo Nordisk (NVO) Denmark $106.636B 17.32
AstraZeneca (AZN) United Kingdom $102.177B 12.69
GlaxoSmithKline (GSK) United Kingdom $100.760B 13.54
Bristol-Myers Squibb (BMY) United States $87.355B 14.39